Literature DB >> 22724479

Inflammaging and proteases in abdominal aortic aneurysm.

Alon Hendel, Lisa S Ang, David J Granville1.   

Abstract

Abdominal aortic aneurysm (AAA) is an age-related disease resulting in aortic wall weakening and dilatation which may progress to the fatal point of abrupt aortic wall rupture. Chronic inflammation is a driving force in the pathogenesis of AAA and extracellular matrix (ECM) proteases are considered central to aortic wall degradation. Considerable effort is dedicated to identifying the proteases responsible as well as the mechanism by which these proteases contribute to disease progression. As such, they are considered important molecular targets for pharmacological intervention. Along with smoking, male gender and family history, aging is a major risk factor for AAA. Examination of age-related changes of the immune system reveals an interwoven relationship between the processes of aging and chronic inflammation, collectively predisposing to AAA development. The present review explores current evidence as to the role of specific ECM proteases in AAA pathogenesis. The contribution of the aging process to disease pathogenesis is also explored to provide the relevant context and highlight key molecular pathways that should be considered while attempting to develop effective treatment approaches.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 22724479     DOI: 10.2174/157016111301150303132348

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  8 in total

1.  FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms.

Authors:  Guillermo Moñux; Jose J Zamorano-León; Pablo Marqués; Bernardo Sopeña; J M García-García; G Laich de Koller; Bibiana Calvo-Rico; Miguel A García-Fernandez; J Serrano; Antonio López-Farré
Journal:  Br J Clin Pharmacol       Date:  2017-08-27       Impact factor: 4.335

Review 2.  Cathepsins: a new culprit behind abdominal aortic aneurysm.

Authors:  Yi Wang; Chaoshu Tang; Yanwen Qin
Journal:  Regen Med Res       Date:  2013-11-01

Review 3.  Computational Hemodynamic Modeling of Arterial Aneurysms: A Mini-Review.

Authors:  Sarah N Lipp; Elizabeth E Niedert; Hannah L Cebull; Tyler C Diorio; Jessica L Ma; Sean M Rothenberger; Kimberly A Stevens Boster; Craig J Goergen
Journal:  Front Physiol       Date:  2020-05-12       Impact factor: 4.566

Review 4.  Extracellular matrix, regional heterogeneity of the aorta, and aortic aneurysm.

Authors:  Sayantan Jana; Mei Hu; Mengcheng Shen; Zamaneh Kassiri
Journal:  Exp Mol Med       Date:  2019-12-19       Impact factor: 8.718

5.  Genome-Wide Identification of Immune-Related Alternative Splicing and Splicing Regulators Involved in Abdominal Aortic Aneurysm.

Authors:  Shiyong Wu; Shibiao Liu; Ningheng Chen; Chuang Zhang; Hairong Zhang; Xueli Guo
Journal:  Front Genet       Date:  2022-02-17       Impact factor: 4.599

Review 6.  Pathogenic mechanisms and the potential of drug therapies for aortic aneurysm.

Authors:  Bo Liu; David J Granville; Jonathan Golledge; Zamaneh Kassiri
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-21       Impact factor: 4.733

7.  Recombinant Decorin Fusion Protein Attenuates Murine Abdominal Aortic Aneurysm Formation and Rupture.

Authors:  Yue Shen; Valerio Russo; Matthew R Zeglinski; Stephanie L Sellers; Zhengguo Wu; Cameron Oram; Stephanie Santacruz; Yulia Merkulova; Christopher Turner; Keerit Tauh; Hongyan Zhao; Tatjana Bozin; Lubos Bohunek; Haishan Zeng; Michael A Seidman; R Chris Bleackley; Bruce M McManus; Erkki Ruoslahti; Tero A H Järvinen; David J Granville
Journal:  Sci Rep       Date:  2017-11-20       Impact factor: 4.379

8.  Participation of Arachidonic Acid Metabolism in the Aortic Aneurysm Formation in Patients with Marfan Syndrome.

Authors:  María E Soto; Verónica Guarner-Lans; Karla Y Herrera-Morales; Israel Pérez-Torres
Journal:  Front Physiol       Date:  2018-02-12       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.